Araris
AcquiredBuilding tomorrow's antibody-drug conjugates
Founded 2019 · $24.0M raised
- Founded
- 2019
- Business Model
- B2B
- Website
- ararisbiotech.com
- Total Funding
- $24.0M
- Last Round
- $24.0M Series AOct 2022
- Rounds
- 1
About
Araris Biotech AG, a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich, is pioneering the development of a novel, proprietary antibody-drug conjugate (ADC)-linker technology. Its linker platform enables payload attachment to off-the-shelf antibodies in one step without needing to re-engineer or reduce antibodies, producing highly homogenous, stable, and potent ADC therapies for cancer treatment.
Summary
Araris is a Biotech company, founded in 2019. It has raised $24.0M in total across 1 round, most recently a $24.0M Series A round in Oct 2022.
Tech & App Stack
3 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Oct 2022
Similar Companies
China's leading blood products manufacturer
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Altos Labs combines academic science and industry development to create medicines that restore ce...
Specialty pharmaceutical company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/araris"><img src="https://indexed.vc/api/badge/company/araris" alt="Araris on Indexed.vc" width="260" height="76" /></a>